Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.49 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.44 |
| ▸ | CCR8 | P51685 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11321990 | 0.86 | L3MBTL1 (0.48) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL890161 | 0.85 | PSMD14 (0.58) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL12131703 | 0.85 | HTR1A (0.53) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL18368389 | 0.80 | KDM4E (0.47) | MEN1KMT2ASMN1; SMN2HTTSLC6A2 | |
| SCHEMBL4029699 | 0.80 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL22031920 | 0.80 | L3MBTL1 (0.42) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL13797358 | 0.80 | CYP2C19 (0.62) | MEN1KMT2ASMN1; SMN2HTTSLC6A2 | |
| SCHEMBL18368378 | 0.80 | L3MBTL1 (0.47) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL812451 | 0.80 | HTT (0.70) | MEN1KMT2ASMN1; SMN2HTTPSMD14 | |
| SCHEMBL13193181 | 0.78 | L3MBTL1 (0.48) | MEN1KMT2ASMN1; SMN2HTTPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3655401-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-4198031-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-3408271-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210371432-A1 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline Compounds for the Treatment of Autoimmune Disease | HOFFMANN-LA ROCHE INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3456717-B1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE | GILEAD SCIENCES INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7468439-B2 | Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080090883-A1 | ALKYLENE BRIDGED SULTAM COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | MEN1 4782/4885KMT2A 2957/4885SMN1; SMN2 4162/4885 |
| US-20210371432-A1 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline Compounds for the Treatment of Autoimmune Disease | HLA-DRB1, SSB, REN | MEN1 45/4885KMT2A 811/4885SMN1; SMN2 1173/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | MEN1 4782/4885KMT2A 2957/4885SMN1; SMN2 4162/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | MEN1 4759/4885KMT2A 2964/4885SMN1; SMN2 3944/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | MEN1 4020/4885KMT2A 3948/4885SMN1; SMN2 2200/4885 |
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, PYGL | MEN1 4842/4885KMT2A 2429/4885SMN1; SMN2 4121/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | MEN1 4800/4885KMT2A 2241/4885SMN1; SMN2 3504/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | MEN1 3521/4885KMT2A 4050/4885SMN1; SMN2 1977/4885 |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | MEN1 3448/4885KMT2A 1119/4885SMN1; SMN2 4787/4885 |
| US-20080090883-A1 | ALKYLENE BRIDGED SULTAM COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | SULT2A1, SULT1A1, NR5A1 | MEN1 3039/4885KMT2A 560/4885SMN1; SMN2 4098/4885 |
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, HRH3 | MEN1 395/4885KMT2A 563/4885SMN1; SMN2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.